British scientists create new form of pancreatic cancer treatment

29 February 2012

By mixing together two chemotherapy drugs, scientists believe they have created a new way of treating pancreatic cancer.

Researchers at Cancer Research UK have been successful in developing a new way to target the cells which cause the severe disease.

The scientists, who are based at the Cambridge Research Institute, focused their study on finding the effects of combining the ABRAXANE cancer treatment with gemcitabine.

Such a mixture was then trialled on pancreatic cells within mice, with the results finding that the amount of active gemcitabine increased as a result.

Looking ahead at further research, study author David Tuveson, group leader at Cancer Research UK's Cambridge Research Institute, said: "Understanding that adding nab-paclitaxel to the mix can boost the effects of gemcitabine suggests other drugs might also be used in combination treatments for pancreatic and other cancers."

Vall d'Hebron Institute of Oncology also recently demonstrated that two cancer drugs which have stopped working received a boost in efficacy when combined to create a new treatment.

Posted by Edward Bartel

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)